Ascendis Pharma A/S ASND
$252.73 −$3.23 (-1.26%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $252.73 0.00%
Open$255.44
Prev close$255.96
Day range$251.55 – $256.65
Volume602.9K
Market cap$16.63B
P/E (TTM)34.7
Dividend yield–
ASND Stock News
Headlines matching Ascendis Pharma A/S or the ASND ticker, most recent first.
- Barclays Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $329
- Oppenheimer Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $312 Positive
- Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $273
- A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $273 to $344
- Wedbush Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $327
- A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $304 to $344
- Raymond James Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $287 Positive
- H.C. Wainwright Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $344
- Evercore Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $329
- Cantor Fitzgerald Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $300
- Barclays Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $345
- H.C. Wainwright Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Cuts Target Price to $344 Negative
- Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $275
- H.C. Wainwright Initiates Ascendis Pharma A/S(ASND.US) With Buy Rating, Announces Target Price $345
- J.P. Morgan Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Announces Target Price $300
No comments yet — be the first to weigh in on ASND.
Sign in to join the discussion.